Dermira (NASDAQ:DERM)‘s stock had its “buy” rating reissued by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. They presently have a $20.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 97.63% from the company’s previous close.
The analysts wrote, “DERM is a leading dermatology company with pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $20. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $20.””
A number of other research firms have also weighed in on DERM. Zacks Investment Research upgraded shares of Dermira from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Tuesday, May 22nd. BidaskClub lowered shares of Dermira from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 19th. Finally, Needham & Company LLC set a $16.00 price target on shares of Dermira and gave the stock a “buy” rating in a research report on Friday, May 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $27.00.
Shares of NASDAQ DERM opened at $10.12 on Wednesday. Dermira has a 52-week low of $6.98 and a 52-week high of $31.42. The stock has a market capitalization of $400.09 million, a PE ratio of -2.31 and a beta of 1.43. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 2.49.
Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.57). The firm had revenue of $39.08 million for the quarter, compared to analyst estimates of $39.00 million. Dermira had a negative net margin of 761.87% and a negative return on equity of 128.21%. research analysts predict that Dermira will post -5.46 earnings per share for the current fiscal year.
In other Dermira news, CEO Thomas G. Wiggans purchased 12,000 shares of the stock in a transaction that occurred on Monday, July 9th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $120,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased 49,805 shares of company stock worth $479,517 over the last 90 days. 14.80% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its stake in Dermira by 31.9% during the first quarter. Wells Fargo & Company MN now owns 32,772 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 7,924 shares during the period. Xact Kapitalforvaltning AB purchased a new position in Dermira during the second quarter worth about $106,000. Alpine Global Management LLC purchased a new position in Dermira during the first quarter worth about $100,000. Barclays PLC raised its stake in Dermira by 276.7% during the first quarter. Barclays PLC now owns 17,499 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 12,854 shares during the period. Finally, Aperio Group LLC raised its stake in Dermira by 126.5% during the second quarter. Aperio Group LLC now owns 24,828 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 13,867 shares during the period. Hedge funds and other institutional investors own 81.39% of the company’s stock.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.